Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 8/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668134 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL29476451 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL30358358 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL11325497 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL31118495 | 0.96 | PTGS1 (0.48) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL31118358 | 0.96 | PTGS1 (0.48) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL29850032 | 0.96 | PTGS1 (0.48) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL31118396 | 0.96 | PTGS1 (0.48) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL31118408 | 0.96 | PTGS1 (0.48) | PTGS1SLC7A11MMEACECPA1 | |
| SCHEMBL30056275 | 0.96 | PTGS1 (0.48) | PTGS1SLC7A11MMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028378-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | LATVIAN INST ORGANIC SYNTHESIS (LV) | 2026-01-29 | — | — | US | claimed |
| EP-4522636-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | Latvian Institute Of Organic Synthesis (LV) | 2025-03-19 | — | — | EP | claimed |
| US-20240279615-A1 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | EVONIK OPERATIONS GMBH (DE) | 2024-08-22 | — | — | US | claimed |
| EP-4402246-A1 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | Evonik Operations GmbH (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2023227926-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2023-11-30 | — | — | WO | claimed |
| EP-4166651-A1 | METHODS AND COMPOSITION TO INCREASE CELLULAR GLUTATHIONE LEVEL | Evonik Operations GmbH (DE) | 2023-04-19 | — | — | EP | claimed |
| WO-2023041295-A1 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | EVONIK OPERATIONS GMBH (DE) | 2023-03-23 | — | — | WO | claimed |
| WO-2023018782-A1 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| EP-4069311-A1 | REACTIVE CONJUGATES | Debiopharm Research & Manufacturing SA (CH) | 2022-10-12 | — | — | EP | claimed |
| CN-101897691-A | Application of isothiocyanate compounds in promoting hair growth | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2010-12-01 | — | — | CN | claimed |
| CN-116583298-B | PD-1 targeted IL-15/IL-15RαFC fusion proteins with improved properties | 基因泰克公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4695412-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12527841-B2 | Fibroblast growth factor-21-Fc fusion proteins | NOVARTIS AG (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-4619412-A2 | PEPTIDES | Carocell Bio Limited (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-20250257095-A1 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2025-08-14 | — | — | US | disclosed |
| US-8026054-B2 | Antibodies against cells of fetal origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-27 | — | — | US | disclosed |
| CN-101897691-A | Application of isothiocyanate compounds in promoting hair growth | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2010-12-01 | — | — | CN | disclosed |
| US-20090011409-A1 | Antibodies Against Cells of Fetal Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1819734-A2 | ANTIBODIES BINDING TO CD34+/CD36+ FETAL BUT NOT TO ADULT CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2005123779-A2 | ANTIBODIES BINDING TO CD34+/CD36+ FETAL BUT NOT TO ADULT CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527841-B2 | Fibroblast growth factor-21-Fc fusion proteins | FGF23, FGFR1, FIBP | PTGS1 3633/4885SLC7A11 3651/4885MME 2440/4885 |
| US-20260028378-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | SGTA, PTMS, SCTR | PTGS1 2391/4885SLC7A11 1889/4885MME 1314/4885 |
| US-20250257095-A1 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | PTMS, CTH, CISD1 | PTGS1 1109/4885SLC7A11 143/4885MME 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.